Cornerstone Capital Management Holdings LLC. acquired a new position in Mednax, Inc (NYSE:MD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 121,309 shares of the company’s stock, valued at approximately $5,229,000. Cornerstone Capital Management Holdings LLC. owned approximately 0.13% of Mednax at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Thompson Siegel & Walmsley LLC lifted its position in Mednax by 95.9% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock worth $131,048,000 after acquiring an additional 1,062,584 shares during the period. Balyasny Asset Management LLC lifted its position in Mednax by 8,590.5% during the 2nd quarter. Balyasny Asset Management LLC now owns 1,060,247 shares of the company’s stock worth $64,007,000 after acquiring an additional 1,048,047 shares during the period. HealthCor Management L.P. acquired a new stake in Mednax during the 2nd quarter worth about $56,913,000. Toronto Dominion Bank lifted its position in Mednax by 19,942.3% during the 3rd quarter. Toronto Dominion Bank now owns 723,928 shares of the company’s stock worth $31,211,000 after acquiring an additional 720,316 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Mednax by 987.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 756,215 shares of the company’s stock worth $32,607,000 after acquiring an additional 686,678 shares during the period. 98.48% of the stock is owned by hedge funds and other institutional investors.

In other Mednax news, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Shares of Mednax, Inc (MD) traded down $0.51 during trading on Friday, hitting $51.07. The company had a trading volume of 1,400,100 shares, compared to its average volume of 1,094,698. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax, Inc has a 1 year low of $40.56 and a 1 year high of $72.13. The stock has a market cap of $4,830.74, a price-to-earnings ratio of 15.77, a PEG ratio of 1.66 and a beta of 0.40.

Mednax (NYSE:MD) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The firm had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. During the same quarter in the previous year, the business earned $1.09 EPS. Mednax’s revenue for the quarter was up 4.9% compared to the same quarter last year. sell-side analysts anticipate that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.

A number of research firms have weighed in on MD. Piper Jaffray Companies began coverage on Mednax in a research note on Wednesday. They set an “overweight” rating and a $58.00 price objective for the company. Jefferies Group reiterated a “hold” rating and set a $46.00 price objective on shares of Mednax in a research note on Tuesday, October 3rd. Robert W. Baird reiterated a “hold” rating and set a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. KeyCorp set a $51.00 price objective on Mednax and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Citigroup reduced their price objective on Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $53.70.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/121309-shares-in-mednax-inc-md-purchased-by-cornerstone-capital-management-holdings-llc/1765732.html.

Mednax Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.